Record overview
Status and phase
Status: RECRUITING
Phase: PHASE1, PHASE2
Sponsor: Merck Sharp & Dohme LLC
Condition: Ovarian Cancer Recurrent
NCT06843447
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.